
DAAN Biotherapeutics
Dianvanio teputics is leading in the development of anti-diabetics and cell therapy for solid cancer.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
* | KRW23.0b | Series A | |
Total Funding | 000k |
DAAN Biotherapeutics is a pioneering company in the field of cancer treatment, focusing on innovative therapies to combat solid tumors. The company specializes in research and development of cell therapies, antibodies, and small molecule inhibitors. DAAN Biotherapeutics primarily serves cancer patients, aiming to provide advanced treatment options where traditional therapies fall short. The company operates in the biopharmaceutical market, leveraging cutting-edge science to develop new immune cell therapies, particularly targeting lung cancer with T Cell Receptor (TCR) based natural killer cells. DAAN Biotherapeutics generates revenue through the development and commercialization of these advanced cancer treatments, collaborating with various partners and stakeholders in the healthcare sector.
Keywords: cancer treatment, cell therapy, antibodies, small molecule inhibitors, T Cell Receptors, solid tumors, lung cancer, biopharmaceutical, immune cell therapy, innovative therapies.